Trial Profile
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 04 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2018 Interim results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Jan 2017 Status changed from not yet recruiting to recruiting.